查看犬血管肉瘤的治疗：2000 年及以后的源代码

== 2000年以后 (Beyond 2000) ==

其他令人兴奋和有前途的犬 HSA 潜在疗法包括使用针对肿瘤细胞表面特定抗原或受体的抗体以及重组血管生成抑制剂的开发。整合素是介导细胞-基质和细胞-细胞相互作用的粘附分子[86,87] 它们在多种生物学事件中很重要，包括细胞分化、恶性转化、免疫功能和凝血[86,87] 整合素在许多细胞表面表达，包括成骨细胞和内皮细胞[86,87] 整合素已在患有骨肉瘤的狗中鉴定出来，并且正在进行研究以确定患有 HSA 的狗的整合素表达水平[87] 整合素家族可作为抗体、化疗药物或细胞生长抑制剂的有吸引力的靶标。

另一个可行的途径是使用重组血管生成抑制剂作为预防转移和肿瘤生长的方法。目前，一种犬重组内皮抑素（一种天然血管生成抑制剂）正在开发中，并可能在不久的将来用于临床试验（Khanna，个人交流）。


Other exciting and promising potential therapies for canine HSA include the use of antibodies directed against specific antigens or receptors on tumor cell surfaces and the development of recombinant angiogenic inhibitors. Integrins are adhesion molecules that mediate cell-matrix and cell-cell interactions.86,87 They are important in several biological events including cell differentiation, malignant transformation, immune functions, and coagulation.86,87 Integrins are expressed on the surface of many cells including osteoblasts and endothelial cells.86,87 Integrins have been identified in dogs with osteosarcoma, and research is underway to determine integrin expression levels in dogs with HSA.87 The integrin families may serve as an attractive target for antibodies, chemotherapeutic agents, or cell growth inhibitors.

Another plausible avenue is the use of recombinant angiogenic inhibitors as a method to prevent metastasis and tumor growth. Currently, a canine recombinant endostatin, a natural angiogenic inhibitor, is being developed and may be used in clinical trials in the near future (Khanna, personal communication).

<br>